Travere Therapeutics Q3 2024 Earnings Report

Travere Therapeutics EPS Results

• Actual EPS: -$0.70
• Consensus EPS: -$0.71
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: -$1.17

Travere Therapeutics Revenue Results

• Actual Revenue: $62.90 million
• Expected Revenue: $60.87 million
• Beat/Miss: Beat by +$2.03 million
• YoY Revenue Growth: +69.60%

Travere Therapeutics Announcement Details

• Quarter: Q3 2024
• Date: 10/31/2024
• Time: Before Market Opens

Travere Therapeutics (NASDAQ:TVTX), a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.